RxDoctor Payments Data

Daniel Nolan, DO

Ophthalmology · San Antonio, TXNPI 1902163025

Payments from drug & device makers

$46,319in general payments, 2019–2025

Across 33 payments — averaging $1403.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$45K
  • Novartis$370
  • Alcon$274
  • Aerie Pharmaceuticals, Inc.$220
  • NEW World Medical,inc.$203
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$94
  • plus $130 from 4 others

What the payments were for

  • Food & beverage$1,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,319 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$429,031
Medicare patients
1,048
Services billed
4,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost290$152,224
RocklatanNetarsudil Mesylat/Latanoprost163$81,937
RhopressaNetarsudil Mesylate166$73,353
SimbrinzaBrinzolamide/Brimonidine Tart109$36,852
Travoprost129$31,410
ProlensaBromfenac Sodium88$30,322
CombiganBrimonidine Tartrate/Timolol46$29,477
Prednisolone Acetate533$26,582
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol128$24,292
VyzultaLatanoprostene Bunod33$15,778
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat968$15,433
Brimonidine Tartrate350$15,383
Latanoprost1,336$14,184
MoxifloxacinMoxifloxacin Hcl505$13,954
RestasisCyclosporine12$12,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$45,027$201,754365 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$220$155,290329 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate$94$39,405125 claims
AlconSimbrinza$274$36,852109 claims
Bausch & Lomb Americas Inc.Vyzulta$60$15,77833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →